Why the study?
Do plasma concentrations of prostacyclin and thromboxane metabolites differ between diabetic patients and non-diabetic controls?
Do plasma concentrations of prostacyclin and thromboxane metabolites differ between diabetic patients and non-diabetic controls?
In diabetic patients with microangiopathy, the balance between prostacyclin and thromboxane A2 appears to be shifted toward prostacyclin dominance.
No takes yet. Share an insight, caveat, or question.
Elevated prostacyclin metabolite in diabetic microangiopathy may indicate shifted eicosanoid balance; hypothesis-generating observational data that should not yet change practice.
Ylikorkala et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: